Guardant Health
Guardant Health
GH
NASDAQ
25.58
USD
-29.24%
About
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer.
It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.3M |
| Three Month Average Volume | 44.9M |
| High Low | |
| Fifty-Two Week High | 40.48 USD |
| Fifty-Two Week Low | 15.81 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 19 Apr 2024 |
| Price and Volume | |
| Current Price | 25.58 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -23.74% |
| Thirteen Week Relative Price Change | -11.81% |
| Twenty-Six Week Relative Price Change | 22.64% |
| Fifty-Two Week Relative Price Change | -47.76% |
| Year-to-Date Relative Price Change | -20.14% |
| Price Change | |
| One Day Price Change | -1.35% |
| Thirteen Week Price Change | -5.61% |
| Twenty-Six Week Price Change | 34.84% |
| Five Day Price Change | -11.85% |
| Fifty-Two Week Price Change | -34.54% |
| Year-to-Date Price Change | -5.43% |
| Month-to-Date Price Change | -27.18% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.30465 USD |
| Book Value Per Share (Most Recent Quarter) | -0.01312 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.20378 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.10283 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.89647 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 5.03579 USD |
| Revenue Per Share (Trailing Twelve Months) | 5.35979 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.28125 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -4.09155 USD |
| Normalized (Last Fiscal Year) | -4.07172 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.28125 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -4.09155 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.28125 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -4.09155 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 9.60812 USD |
| Cash Per Share (Most Recent Quarter) | 7.59289 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.89835 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.725 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.49141 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -66 |
| Cash Flow Revenue (Trailing Twelve Months) | -46 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -76.15% |
| Pretax Margin (Last Fiscal Year) | -84.90% |
| Pretax Margin (5 Year) | -97.04% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 59.74% |
| Gross Margin (Trailing Twelve Months) | 59.95% |
| Gross Margin (5 Year) | 64.62% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -106.54% |
| Operating Margin (Trailing Twelve Months) | -80.51% |
| Operating Margin (5 Year) | -99.24% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -85.02% |
| Net Profit Margin (Trailing Twelve Months) | -76.23% |
| Net Profit Margin (5 Year) | -97.07% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -25.35% |
| Tangible Book Value (5 Year) | -21.24% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 29.23% |
| Revenue Growth (3 Year) | 44.14% |
| Revenue Change (Trailing Twelve Months) | 26.20% |
| Revenue Per Share Growth | 36.67% |
| Revenue Growth (5 Year) | 25.29% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 0.28% |
| Total Debt (5 Year) | 455.25% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -25.32% |
| EPS Change (Trailing Twelve Months) | 16.81% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 21 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 207.6M |
| Net Debt (Last Fiscal Year) | -28,668,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 6 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 20 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 718 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 6 |
| Quick Ratio (Most Recent Quarter) | 6 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -345,461,000 |
| Free Cash Flow (Trailing Twelve Months) | -299,265,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -12 |
| Net Interest Coverage (Trailing Twelve Months) | -10 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 718 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -28.23% |
| Return on Assets (Trailing Twelve Months) | -28.46% |
| Return on Assets (5 Year) | -22.26% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -438.13% |
| Return on Equity (Trailing Twelve Months) | -337.16% |
| Return on Equity (5 Year) | -59.85% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -31.99% |
| Return on Investment (Trailing Twelve Months) | -32.21% |
| Return on Investment (5 Year) | -24.59% |